Radiation Oncologist, Associate Professor at @NorthwesternMed @LurieCancer. #radonc #btsm #pcsm tweets = own opinion
Chicago, IL
- Tweets 1,667
- Following 1,068
- Followers 1,906
- Likes 7,988
Sean Sachdev, MD retweeted
Let’s not forget the BRIGHT trial (@SWOG S2427) -Phase II study evaluating a bladder-preservation strategy for patients with #MIBC who achieve a meaningful response to neoadjuvant therapy—using pembrolizumab + radiation instead of immediate radical cystectomy in carefully selected patients. @l_ballas @AbhiTrip87 @MarkTysonMD @mouwlab @JoshMeeks @djmcconkey @KyleRoseMD @DrKarineTawagi @SeanSachdevMD @kritimittalmd
If a patient in front of you refuses RC after EVP, the honest answer is enrollment in a prospective surveillance protocol with predefined imaging and biopsy triggers for salvage therapy. (EV-209; NCT07475806)
NOT quiet endorsement of surveillance as standard of care.
@scserendipity1 @tompowles1 @AndreaNecchi @shilpaonc @siadaneshmand @UrogerliMD @bbmdmsk @joanfundi @IBCG_BladderCA @drenriquegrande @JoshMeeks
9
33
4,805
Adaptive radiotherapy involves modifying treatment plans to account for changes in anatomical geometry that are not adequately mitigated with changes in alignment. Online adaptive radiotherapy capitalizes on advances in image guidance, real-time tumor tracking, and the enhanced speed of multiple steps in radiotherapy planning and delivery workflows (seen in image).
Learn more in the Review Article “Effects of Radiotherapy in Normal Tissue” by @DeborahCitrin, MD, and Robert D. Timmerman, MD (@BobTimmermanMD), from the National Cancer Institute and @UTSWMedCenter: nejm.org/doi/full/10.1056/NE…
ALT Figure 5. Online and Offline Approaches to Adaptive Radiotherapy. In both online and offline approaches, the patient undergoes a simulation and treatment planning. On the day of treatment delivery, a pretreatment image is obtained and compared with a reference (planning) image. If the alignment is within an acceptable range, the treatment is delivered. If the alignment is outside the acceptable range or if marked anatomical changes are noted, the treatment must be replanned. With online adaptive approaches, replanning and quality assurance (QA) occur while the patient remains on the treatment table, and the new treatment is delivered without delay. Online adaptive approaches are resource-intensive and require real-time availability of radiation oncologists, physicists, and dosimetrists. Offline approaches allow for the care team to prepare a new plan without real-time availability, but a delay or break in the treatment may occur.
1
59
136
15,640
Excellent deep dive by @DrKarineTawagi on the modern systemic landscape for MIBC. A comprehensive look at current standards and the future considerations shaping the field. 🧬 #UroOnc #BladderCancer @ChiUroSociety
2
12
890
Sean Sachdev, MD retweeted
PRO bladder preservation @SeanSachdevMD vs PRO cystectomy debate @ChiUroSociety urothelial meeting
#GU015 trial ongoing looking at SBRT vs hypofractionated RT in TMT
Framework for pt selection for TMT by @shilpaonc et al @EuropeanUrology
💡proposed framework for the future
2
10
45
2,185
Sean Sachdev, MD retweeted
Extremely excited to share our latest article published @TheLancetOncol a few hours ago: authors.elsevier.com/a/1mYT6….
The WOLVERINE individual patient meta-analysis was an international collaboration and part of X-MET collaboration. Goal was to evaluate MDT in oligomet prostate ca.
11
52
140
14,274
Sean Sachdev, MD retweeted
Great to reconnect with so many motivated clinical trialists, colleagues, and the #GU family at the @NRGOnc Winter Meeting #NRG2026!
2025 was a big year for NRG GU with landmark trials presented at ASTRO in plenary and clinical trials sessions (GU005, RTOG 0924, GU006) and two major bladder trials that were launched:
🔹 NRG GU014 PARRC 💉 — RT+IO vs chemoRT in NMIBC
🔹 NRG GU015 ARCHER 🏹 — 20 vs 5 (adaptive) fractions chemoRT in MIBC
Lots more to come in 2026! Grateful to the PIs and study teams—and especially to the patients and families who make NRG trials possible.
@snseyedinMD @jmmrad @DrHowardSandler @NehaVapiwala @DrPaulNguyen @RonaldChenMD @MaryFengMD @ChadTangMD @KHoffmanMD @BrianBaumannMD @CaPsurvivorship @EdwinPosadasMD @MiyamotoDavid @abhiAsolanki @bridget_koontz @MoningiShalini @HimanshuNagarMD @UroCancer @DrSpratticus @Katie_Spina @TylerSbrt @sophia_kamran @tranpt21 @aleberlin2 @a_dalpra @ndesai2005 @SeanSachdevMD @MassGenBrigham @NRGonc
#NRGOncology #RadiationOncology #GUCancer #CancerResearch #OncologyCommunity #BladderCancer #ClinicalTrials #TeamScience
6
26
2,942
Sean Sachdev, MD retweeted
🏹 Randomized Phase III Trial: Adaptive Radiation and Chemotherapy For Muscle Invasive Bladder Cancer (ARCHER)
Congratulations to the NRG GU015 ARCHER study team led by @UroCancer and @HimanshuNagarMD for the recent activation and launch of this cutting-edge and patient-centric bladder-sparing phase III trial that investigates many novel interventions including ultrahypofractionation/SBRT, adaptive radiation, ctDNA as a biomarker, and allows for any neoadjuvant systemic therapy. Please support this important study!
#CancerResearch #RadiationOncology #Urology #MedicalOncology #MIBC #ClinicalTrial #ClinicalResearch
@DrPaulNguyen @Shilpaonc @danielxingao @SeanSachdevMD @KellyStratton @AdityaBagrodia @ndesai2005 @Jonathan_Leeman @KashaniRojano @KateMRGuidance @DrMBWesterman @abhiAsolanki @MiyamotoDavid @Katie_Spina @jamesmgtsui @NRGOnc @MGHCancerCenter @urotoday @BladderCancerUS @MassGenBrigham
PRESS RELEASE: NRG Oncology Opens New “ARCHER” Clinical Trial (NRG-GU015) Testing a Shorter Treatment Duration of Radiation Therapy for Muscle Invasive Bladder Cancer - Read more: ow.ly/6lyF50WG0GN @UroCancer @HimanshuNagarMD @MSKCancerCenter
7
12
56
8,215
Sean Sachdev, MD retweeted
On Monday, I will present the key PARTIQoL trial results at the 2024 @ASTRO_org Annual Meeting! 🎉 I'll cover the potential benefits of #ProtonTherapy, & innovative patient recruitment strategies. Let me know if you are attending #ASTRO2024 too!
1
11
36
4,249
Honored to host Dr. Albert Koong @ACKoongMDPhD, Chair of RadOnc at MD Andreson, as the distinguished speaker for our annual resident retreat. He started us off with a wonderful talk this morning.
2
23
1,838
Really honored and humbled to receive the 2024 Christopher Getch Clinical Excellence Award from @NeurosurgeryNM
Proud to participate in the care of brain tumor patients and contribute to the education of neurosurgery residents #btsm
6
5
61
4,216
Sean Sachdev, MD retweeted
ASTRO PLENARY Session LBA 04 Randomized trial PCI vs HA-PCI:
HA-PCI is a standard of care for Small cell lung cancer
1
37
85
10,473
ASTRO Plenary: 5-fraction SBRT/SABR non-inferior at 5y compared to more protracted treatment (PACE-B). Detailed toxicity reporting, great work by @nickva1 @alison_tree @ICR_CTSU #ASTRO23
2
5
1,149
Sean Sachdev, MD retweeted
👩🏫📚🎉 Congratulations to our Dr. Luther Brady Educational Grant winners! 🎉📚👩🏫
Amulaya Yalamanchili, Northwestern University, @amulyayala
Michelle Tibbs @UCSDRadMed @shelley_tibbs
Ramez Kouzy @MDAndersonNews @RKouzyMD
Michael Rooney @MDAndersonNews @MichaelRooney67
1
3
18
7,281
Sean Sachdev, MD retweeted
Had a blast giving a talk and hanging out with @NorthwesternMed #radonc residents and students as visiting professor! The future is bright for our field! 🌟☢️ @SeanSachdevMD @JamesRandallMD1
@SalahDajaniMD @AmulyaYala @George_E_Naoum @Zheng_Shuhua @WashURadOnc
4
7
59
5,548
Sean Sachdev, MD retweeted
TRIP did not demonstrate the superiority of 30 months vs. 6 months of ADT when combined with brachytherapy and EBRT.! Atsunori Yorozu, MD, PhD
#GU23 @ASCO @OncoAlert @urotoday @PCFnews @OncBrothers @APCCC_Lugano @HemOncFellows
#prostatecancer @Uromigos #MedTwitter
3
17
38
20,013
Sean Sachdev, MD retweeted
Mature outcome data from the landmark, practice changing CHHIP trial presented by @ProfJOSullivan @QubPGJCCR. 60Gy very close to being superior to 74Gy. Superb data. @EmmaHall71 @ICR_CTSU #GU23
18
48
4,575
Sean Sachdev, MD retweeted
🔥🔥 primary endpoint analysis from @nickva1 of PACE-A; SBRT versus robotic prostatectomy for #prostatecancer RCT. Co-primary toxicity endpoints (continence/bowel) #GU23 @ASCO @OncoAlert @NHSuk. N=123, SBRT had ⬇️ pad use ⬇️ sexual dysfunction but ⬆️ bowel bother. All low grade.
2
50
124
17,051
The @atiqueahmedphd lab showing that ARF4 upregulation may serve to increase treatment resistance; a potential target for improved outcomes in GBM. #SNO2022 #btsm
4
12